The role of lapatinib in HER2-positive breast cancer
Journal Title: OncoReview - Year 2013, Vol 3, Issue 2
Abstract
HER2 positive breast cancer presents 25–35% of newly diagnosed cases and is associated with more aggressiveness and poorer prognosis. The anti-HER2 monoclonal antibody trastuzumab improved the outcome of women with HER positive breast cancer. Despite the primary effectiveness resistance to trastuzumab occurs. The second drug which interacts with HER2 receptor is lapatinib. There is no cross resistance between both drugs. Lapatinib is dual, reversible tyrosin kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Based on the results of the clinical trials the efficacy and safety of lapatinib was confirmed.
Authors and Affiliations
Małgorzata Kuc-Rajca, Tadeusz Pieńkowski, Anna Walaszkowska-Czyż
Keywords
Related Articles
- EP ID EP53216
- DOI -
- Views 207
- Downloads 0
Recurrent invasive pulmonary aspergillosis or breakthrough fungal infection in a child after haploidentical hematopoietic stem cell transplantation
Invasive fungal infections (IFI) are devastating and life threatening infections affecting especially immunocompromised patients. We report on a case of a 14-year-old boy with myelodysplastic syndrome (MDS), after haplo...
Should a diagnosis of cancer impact the anticoagulant therapy in patients with recurrent thromboembolic disease?
Venous thromboembolism often coexists with cancer, deteriorating patient prognosis. The diagnosis of cancer in patients who suffer from venous thromboembolism may lead to changes in the anticoagulant therapy administered...
Treatment of multiple superficial basal cell carcinomas with topical imiquimod
Basal cell carcinoma is the most common malignancy of man. The use of the topical imiquimod 5% cream offers a noninvasive, nonsurgical, and an effective option for the treatment of primary types superficial basal cell ca...
Antyproliferacyjne działanie analogów somatostatyny - przesłanie z badania PROMID
New data concerning treatment of urogenital cancer patients presented at annual congress of American Society of Clinical Oncology 2011
INTRODUCTION: The annual congress of The American Society of Clinical Oncology took place between 03.06.2011 and 06.06.2011 in Chicago, the US.MATERIAL AND METHODS: Papers presented during ASCO are discussed in four sect...